Amesite Inc. reports 63% revenue growth for its NurseMagic™ platform, driven by new enterprise subscription model and regulatory automation solutions.
Quiver AI Summary
Amesite Inc. announced a 63% revenue growth for its NurseMagic™ platform following the introduction of a census-based Enterprise subscription model on July 14, 2025. This shift has resulted in enterprise sales outpacing B2C sales as post-acute care providers seek scalable technology that ensures full reimbursement rates. The company also revealed a new AI-powered automated form fill feature designed to streamline compliance with government documentation requirements, particularly as the CMS prepares to mandate the Hospice Outcomes and Patient Evaluation (HOPE) assessment. Amesite's solutions are aimed at reducing the administrative burden on healthcare providers, enabling them to operate more efficiently without increasing staff. CEO Dr. Ann Marie Sastry emphasized the platform’s unique approach compared to traditional EMR vendors, highlighting its potential to give customers a competitive edge in a rapidly growing post-acute care market.
Potential Positives
- 63% revenue growth for the NurseMagic™ platform indicates strong market acceptance and demand for the new Enterprise subscription model.
- Enterprise sales have surpassed B2C sales, highlighting a shift towards scalable solutions for organizations, particularly in post-acute care.
- The launch of AI-powered automated form fill for government documentation positions Amesite as a proactive solution provider amid increasing regulatory burdens in healthcare.
- Amesite's focus on leveraging AI technology aims to provide a competitive edge, crucial for organizations navigating a rapidly growing post-acute care market.
Potential Negatives
- The announcement highlights a significant regulatory burden looming with the Healthcare Outcomes and Patient Evaluation (HOPE) assessment, which may strain the company’s customers and, by extension, its sales if organizations struggle to adapt.
- Despite reporting strong revenue growth for its NurseMagic™ platform, the need for urgent solution uptake due to impending regulatory changes may suggest that the company's growth is reactive rather than a result of strategic expansion.
- The emphasis on the need for compliance with increasing documentation scrutiny may indicate that organizations are facing operational difficulties, which could hinder long-term customer retention and satisfaction with Amesite’s products.
FAQ
What revenue growth did Amesite announce for NurseMagic™?
Amesite reported a 63% revenue growth for its NurseMagic™ platform following the launch of its Enterprise subscription model.
How does NurseMagic™ support post-acute care providers?
NurseMagic™ helps post-acute care providers by offering scalable, compliant technology that facilitates full reimbursement rates.
What is the HOPE automation solution in NurseMagic™?
The HOPE automation solution enables organizations to auto-populate complex forms, reducing administrative time and ensuring compliance.
How does Amesite differentiate from traditional EMR vendors?
Amesite reimagines document handling for post-acute care organizations, focusing on leveraging AI to scale operations without additional staff.
What industries does Amesite's NurseMagic™ target?
Amesite's NurseMagic™ targets the home and healthcare segments, serving both B2B and B2C users across various locations.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMST Hedge Fund Activity
We have seen 6 institutional investors add shares of $AMST stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOVITZ INVESTMENT GROUP PARTNERS, LLC added 32,402 shares (+23.8%) to their portfolio in Q2 2025, for an estimated $87,161
- CITADEL ADVISORS LLC removed 22,992 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $61,848
- TWO SIGMA INVESTMENTS, LP added 21,579 shares (+inf%) to their portfolio in Q2 2025, for an estimated $58,047
- RENAISSANCE TECHNOLOGIES LLC removed 12,200 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $29,524
- TWO SIGMA SECURITIES, LLC removed 10,589 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $28,484
- HRT FINANCIAL LP removed 10,438 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $28,078
- STATE STREET CORP removed 8,755 shares (-21.7%) from their portfolio in Q2 2025, for an estimated $23,550
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DETROIT, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, today announced 63% revenue growth for its NurseMagic™ platform following the launch of its census-based Enterprise subscription model on July 14, 2025. Enterprise sales have now surpassed B2C sales, reflecting rising demand from post-acute care providers seeking scalable, compliant technology designed to deliver full reimbursement rates. Amesite also announces the launch of its AI-powered automated form fill for required government forms.
"We’re no longer just selling to employees – we’re selling to serve every patient in the system and help organizations leverage AI technology as a true competitive advantage," said Brandon Owens, VP of Sales at Amesite. "That changes the game. The total addressable market is exponentially larger, and our pricing reflects the performance of our solution. Customers are choosing NurseMagic™ Enterprise to scale operations without adding staff, addressing one of the greatest costs in healthcare."
The announcement comes as the Centers for Medicare & Medicaid Services (CMS) prepares to mandate the Hospice Outcomes and Patient Evaluation (HOPE) assessment this October – a regulatory overhaul expected to significantly increase documentation burden per patient and strain already thin hospice staffing cohort. Amesite’s AI-powered HOPE automation solution, within NurseMagic™ Enterprise, is designed to enable organizations to auto-populate complex forms, cut administrative time, and assure full reimbursements.
"The government’s scrutiny of documentation is intensifying, and many organizations are unprepared," said Kalie Wortinger, Senior Engineering Manager at Amesite. "With the HOPE requirement looming, providers are seeking a solution that enables compliant, reimbursable submission of documentation. NurseMagic™ Enterprise has modular intelligence that enables our customers to document compliantly, and to be fully reimbursed for the crucial work they do."
"We’ve taken an entirely different approach from traditional EMR vendors," said Dr. Ann Marie Sastry, CEO of Amesite. "Our platform reimagines how post-acute care organizations handle regulatory requirements, enabling them to leverage our AI-powered tools to scale operations without adding staff. We specifically designed our solution to be an essential edge for customers, in a highly competitive, and demographically inevitable, market."
The post-acute care market is growing faster than the acute care market at a CAGR of 8% .
Post-acute care owners can book a demo to learn more about NurseMagic™’s HOPE solution here .
About Amesite Inc.
Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the $330 billion home and healthcare segments. Its flagship product, NurseMagic™, streamlines healthcare documentation, reducing the time required from 20 minutes to just 20 seconds. NurseMagic™ is used by over 100 professions to improve care, enhance operational efficiency and improve financial performance. Built on proprietary AI trained on industry-specific data, NurseMagic meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages.
Forward-Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
